June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Stereopure oligonucleotides promote USH2A exon skipping for the treatment of Usher syndrome type 2A
Author Affiliations & Notes
  • Michael Byrne
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Vinod Vathipadiekal
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Qiong Shen
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Lankai Guo
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Qianli Pan
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Lauren Norwood
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Richard Looby
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Andrew Hoss
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Snehlata Tripathi
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Timea Kolozsvary
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Pachamuthu Kandasamy
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Naoki Iwamoto
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Hailin Yang
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Yuan Yin
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Fangjun Liu
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Chandra Vargeese
    Biology, WAVE Life Sciences, Cambridge, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Michael Byrne, Wave Life Sciences (E); Vinod Vathipadiekal, Wave Life Sciences (E); Qiong Shen, Wave Life Sciences (E); Lankai Guo, Wave Life Sciences (E); Qianli Pan, Wave Life Sciences (E); Lauren Norwood, Wave Life Sciences (E); Richard Looby, Wave Life Sciences (E); Andrew Hoss, Wave Life Sciences (E); Snehlata Tripathi, Wave Life Sciences (E); Timea Kolozsvary, Wave Life Sciences (E); Pachamuthu Kandasamy, Wave Life Sciences (E); Naoki Iwamoto, Wave Life Sciences (E); Hailin Yang, Wave Life Sciences (E); Yuan Yin, Wave Life Sciences (E); Fangjun Liu, Wave Life Sciences (E); Chandra Vargeese, Wave Life Sciences (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2448. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Byrne, Vinod Vathipadiekal, Qiong Shen, Lankai Guo, Qianli Pan, Lauren Norwood, Richard Looby, Andrew Hoss, Snehlata Tripathi, Timea Kolozsvary, Pachamuthu Kandasamy, Naoki Iwamoto, Hailin Yang, Yuan Yin, Fangjun Liu, Chandra Vargeese; Stereopure oligonucleotides promote USH2A exon skipping for the treatment of Usher syndrome type 2A. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2448.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Wave Life Sciences has developed PRISMTM, our proprietary discovery and drug development platform that enables us to target genetically defined diseases with stereopure oligonucleotides. PRISM combines our unique ability to construct stereopure oligonucleotides with a deep knowledge of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties. Here, we report the application of PRISM for the development of stereopure exon-skipping oligonucleotides as a potential disease-modifying therapy for Usher syndrome type 2A.

Methods : Stereopure oligonucleotides targeting exon 13 of the USH2A mRNA transcript were generated using PRISM. Exon-skipping was evaluated under gymnotic conditions in vitro in the Y79 human retinoblastoma cell line. Skipping of the target exon was evaluated by qPCR. The size of skipped product was determined by a gel-shift assay evaluating exons 8-17. RNA-Seq analysis was used to detect and quantify RNA junctions and the presence of skipped transcript. Exon skipping was evaluated ex vivo in non-human primate (NHP) and human retina culture systems. In vivo target engagement was evaluated in wild type NHPs and humanized transgenic mice following a single intravitreal injection of stereopure oligonucleotide.

Results : Stereopure oligonucleotides targeting USH2A induced more potent exon skipping relative to a stereorandom Reference oligonucleotide in cultured cells. We used multiple assays to confirm the presence of the skipped transcript. We also show that our stereopure oligonucleotide induced dose-dependent exon skipping in ex vivo NHP and human retinas. Finally, we demonstrate in vivo target engagement in humanized transgenic mice and NHPs following a single intravitreal injection of stereopure oligonucleotide.

Conclusions : These results indicate that stereopure oligonucleotides generated with PRISM potently induce USH2A exon 13 skipping in multiple model systems. These data support further development of stereopure oligonucleotides as a potential treatment for patients with Usher syndrome type 2A.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×